Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2012

01-11-2012 | Head and Neck Oncology

Risk Stratification in Oral Cavity Squamous Cell Carcinoma by Preoperative CRP and SCC Antigen Levels

Authors: Shiang-Fu Huang, MD, PhD, Fu-Chan Wei, MD, Chun-Ta Liao, MD, Hung-Ming Wang, MD, Chien-Yu Lin, MD, Steven Lo, MD, Jung-Ju Huang, MD, I-How Chen, MD, Chung-Jan Kang, MD, Huei-Tzu Chien, MS, Hsuan-Ho Chen, MD

Published in: Annals of Surgical Oncology | Issue 12/2012

Login to get access

Abstract

Background

Squamous cell carcinoma antigen (SCC-Ag) level and C-reactive protein (CRP) have been shown to be associated with tumor invasion, lymph node metastasis, staging and survival in patients with oral squamous cell carcinoma (OSCC). The purpose of the present study was to analyze the relationship between preoperative levels of both SCC-Ag and CRP, with clinicopathologic factors and prognosis in OSCC patients.

Methods

A retrospective study was performed on 142 OSCC patients between March 2008 and March 2011. Their serum SCC-Ag and CRP levels were measured preoperatively.

Results

SCC-Ag level of ≥2.0 ng/ml and CRP level ≥5.0 mg/L were significantly associated with pathologic tumor status (P < 0.001), pathologic nodal metastasis (P = 0.001), tumor depth (≥10 mm vs. <10 mm, P < 0.001), disease-free survival (P ≤ 0.001) and overall survival (P ≤ 0.001). The influence of SCC-Ag and CRP level on disease-free survival (hazard ratio 4.046, 95 % confidence interval 1.698–9.692) and overall survival (hazard ratio 3.655, 95 % confidence interval 1.464–9.130) still existed after adjusting for tumor status, lymph node metastasis and tumor cell differentiation.

Conclusions

Concurrent high levels of both preoperative SCC-Ag and CRP levels act as a predictor for lymph node metastasis, advanced tumor stage and tumor recurrence. It therefore has significant potential as a biomarker for risk stratification in OSCC.
Appendix
Available only for authorised users
Literature
1.
2.
Liao CT, Wang HM, Ng SH, et al. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol. 2006;42:800–9.PubMedCrossRef
3.
O’Brien CJ, Traynor SJ, McNeil E, McMahon JD, Chaplin JM. The use of clinical criteria alone in the management of the clinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg. 2000;126:360–5.PubMed
4.
Lin WH, Chen IH, Wei FC, et al. Clinical significance of preoperative squamous cell carcinoma antigen in oral-cavity squamous cell carcinoma. Laryngoscope. 2011;121:971–7.PubMedCrossRef
5.
Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF. Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol. 2011;36:147–53.PubMedCrossRef
6.
Söderlund K, Stål O, Skoog L, Rutqvist LE, Nordenskjöld B, Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:50–8.PubMedCrossRef
7.
Kato H, Tamai K, Morioka H, Nagai M, Nagaya T, Torigoe T. Tumor-antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer. 1984;54:1544–6.PubMedCrossRef
8.
Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21–1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer. 2000;89:1413–7.PubMedCrossRef
9.
Margolis ML, Hyzy JB, Schenken LL, Schepart BS. Serum tumor markers in non-small cell lung cancer. A comparative analysis. Cancer. 1994;73:605–9.PubMedCrossRef
10.
Pectasides D, Bafaloucos D, Antoniou F, et al. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19–9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol. 1996;19:271–7.PubMedCrossRef
11.
Petrelli NJ, Shaw N, Bhargava A, et al. Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. J Clin Oncol. 1988;6:782–5.PubMed
12.
Eibling DE, Johnson JT, Wagner RL, Su S. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope. 1989;99:117–24.PubMedCrossRef
13.
Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217–24.PubMedCrossRef
14.
Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRef
15.
McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64–9.PubMed
16.
Suh SY, Ahn HY. A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer. 2007;15:613–20.PubMedCrossRef
17.
18.
19.
Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66:2483–7.PubMedCrossRef
20.
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, editors. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
21.
Huang SF, Kang CJ, Lin CY, et al. Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer. 2008;112:1066–75.PubMedCrossRef
22.
Liao CT, Chang JT, Wang HM, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915–22.PubMedCrossRef
23.
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977, 40:1621–8.PubMedCrossRef
24.
25.
Takeda A, Kajiya A, Iwasawa A, Nakamura Y, Hibino T. Aberrant expression of serpin squamous cell carcinoma antigen 2 in human tumor tissues and cell lines: evidence of protection from tumor necrosis factor–mediated apoptosis. Biol Chem. 2002;383:1231–6.PubMedCrossRef
26.
Sueoka K, Nawata S, Nakagawa T, et al. Tumor-associated serpin, squamous cell carcinoma antigen stimulates matrix metalloproteinase-9 production in cervical squamous cell carcinoma cell lines. Int J Oncol. 2005;27:1345–53.PubMed
27.
Brioschi PA, Bischof P, Delafosse C, Krauer F. Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer. 1991;47:376–9.PubMedCrossRef
28.
Meier W, Eiermann W, Stieber P, Schneider A, Fateh-Moghadam A, Hepp H. Experiences with SCC antigen, a new tumor marker for cervical carcinoma. Eur J Cancer Clin Oncol. 1989;25:1555–9.PubMedCrossRef
29.
Neunteufel W, Tatra G, Bieglmayer C. Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls. Arch Gynecol Obstet. 1989;246:243–50.PubMedCrossRef
30.
Ngan HY, Chan SY, Wong LC, Choy DT, Ma HK. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol. 1990;37:260–3.PubMedCrossRef
31.
Scambia G, Panici PB, Baiocchi G, et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol. 1991;164:631–6.PubMed
32.
Senekjian EK, Young JM, Weiser PA, Spencer CE, Magic SE, Herbst AL. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol. 1987;157:433–9.PubMed
33.
Kimura Y, Fujieda S, Takabayashi T, Tanaka T, Sugimoto C, Saito H. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Cancer Lett. 2000;155:163–8.PubMedCrossRef
34.
Lachowicz MA, Hassmann-Poznanska E, Kozlowski MD, Rzewnicki I. Squamous cell carcinoma antigen in patients with cancer of the larynx. Clin Otolaryngol Allied Sci. 1999;24:270–3.PubMedCrossRef
35.
Lara PC, Cuyas JM. The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer. 1995;76:758–64.PubMedCrossRef
36.
Molina R, Torres MD, Moragas M, et al. Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumour Biol. 1996;17:81–9.PubMedCrossRef
37.
Yasumatsu R, Nakashima T, Azuma K, et al. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue. Cancer Lett. 2001;167:205–13.PubMedCrossRef
38.
Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J Craniomaxillofac Surg. 1998;26:243–8.PubMedCrossRef
39.
Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1–24.PubMedCrossRef
40.
Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32:471–82.PubMed
41.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.PubMedCrossRef
42.
43.
McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–9.PubMedCrossRef
44.
Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94:1568–71.PubMed
45.
Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–64.PubMedCrossRef
46.
Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women’s Heart and Health Study. Cancer Epidemiol Biomarkers Prev. 2007;16:1155–9.PubMedCrossRef
47.
Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20:15–26.PubMedCrossRef
48.
McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006;77:127–9.PubMedCrossRef
49.
Gallo O, Gori AM, Attanasio M, et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol. 1995;252:159–62.PubMedCrossRef
50.
Jablonska E, Piotrowski L, Grabowska Z. Serum Levels of IL-1β, IL-6, TNF-α, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res. 1997;3:126–9.PubMedCrossRef
51.
Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45:912–4.PubMedCrossRef
52.
Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol 2010;2:21.PubMedCrossRef
Metadata
Title
Risk Stratification in Oral Cavity Squamous Cell Carcinoma by Preoperative CRP and SCC Antigen Levels
Authors
Shiang-Fu Huang, MD, PhD
Fu-Chan Wei, MD
Chun-Ta Liao, MD
Hung-Ming Wang, MD
Chien-Yu Lin, MD
Steven Lo, MD
Jung-Ju Huang, MD
I-How Chen, MD
Chung-Jan Kang, MD
Huei-Tzu Chien, MS
Hsuan-Ho Chen, MD
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2392-5

Other articles of this Issue 12/2012

Annals of Surgical Oncology 12/2012 Go to the issue

Breast Oncology

Does the Rapid Acceptance of ACOSOG Z0011 Compromise Selection of Systemic Therapy?

Palliative Care

Palliative Surgical Outcomes: Are We Looking Through a Keyhole?

Head and Neck Oncology

Robot-assisted Supraomohyoid Neck Dissection via a Modified Face-lift or Retroauricular Approach in Early-stage cN0 Squamous Cell Carcinoma of the Oral Cavity: A Comparative Study with Conventional Technique

Hepatobiliary Tumors

A Comprehensive Meta-regression Analysis on Outcome of Anatomic Resection Versus Nonanatomic Resection for Hepatocellular Carcinoma

Melanomas

Lymphatic Drainage Patterns from Melanomas on the Shoulder or Upper Trunk to Cervical Lymph Nodes and Implications for the Extent of Neck Dissection

Breast Oncology

A Randomized, Controlled Trial Comparing Acetaminophen Plus Ibuprofen versus Acetaminophen Plus Codeine Plus Caffeine (Tylenol 3) after Outpatient Breast Surgery